NOW ENROLLING

ARCT-810-04: A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of **ARCT-810** in Adolescent and Adult Participants with Ornithine Transcarbamylase Deficiency

NCT: 06488313

STUDY OVERVIEW

PURPOSE

To evaluate the safety and tolerability of ARCT-810 and its efficacy in restoring urea cycle function. Urea cycle function will be measured through clinical biomarkers and other study assessments.

TREATMENT

There is no placebo in this study. If eligible, participants will receive 5 doses of ARCT-810 via intravenous (IV) infusion every two weeks at one of three dose levels.

DURATION

There will be approximately 13 study visits over a 16-week period (including screening visit).

LOCATION

Uncommon Cures
Chevy Chase, Maryland

What is ARCT-810?

ARCT-810 is an investigational mRNA treatment designed to treat the root cause of OTC deficiency. The mRNA in ARCT-810 acts as a template for making the OTC enzyme. Arcturus uses its proprietary LUNAR® lipid nanoparticle technology to deliver the mRNA template for OTC to the liver, where the OTC enzyme is made.

Who can participate?

- Females and males 12 years of age or older with confirmed diagnosis of OTC deficiency
- Medical history of ammonia or glutamine elevations
- Currently receiving stable therapy and/or dietary interventions for OTC deficiency
- Other requirements apply

Those who qualify will receive all study-related laboratory tests, medical exams, and travel at no cost.

Scan the QR code to learn more about the **ARCT-810-04** study or visit ClinicalTrials.gov **NCT06488313**

For all other questions, please contact **Community@ArcturusRx.com.**

ARCTURUS® therapeutics

Arcturus Therapeutics | www.ArcturusRx.com
Arcturus Therapeutics | Community@ArcturusRx.com
@ArcturusRx

© 2024 Arcturus Therapeutics, Inc. All rights reserved. | May 2024

LUNAR-OTC